FR940523-2-00058 FR940523-2-00038 [Docket No. 94N&hyph;0181] Fujisawa USA, Inc., et al.; Withdrawal of Approval of 22 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 22 abbreviated new drug applications (ANDA's). The holders of the ANDA's notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. EFFECTIVE DATE: June 22, 1994. FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD&hyph;360), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1038. SUPPLEMENTARY INFORMATION: The holders of the ANDA's listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing. 1ANDA no. 1Drug 1Applicant 70&hyph;223 Sulfamethoxazole and Trimethoprim Concentrate for Injection, USP, 80 milligrams (mg)/milliliters (mL) and 16 mg/mL Fujisawa USA, Inc., Parkway North Center, Three Parkway North, Deerfield, IL 60015&hyph;2548. 70&hyph;411 Vincristine Sulfate Injection, USP, 1 mg/mL Do. 71&hyph;270 Tolazamide Tablets, 250 mg Interpharm, Inc., 3 Fairchild Ave., Plainview, NY 11803. 71&hyph;271 Tolazamide Tablets, 500 mg Do. 71&hyph;299 Sulfamethoxazole and Trimethoprim Tablets, USP, 400 mg/80 mg Do. 71&hyph;300 Sulfamethoxazole and Trimethoprim Tablets, USP, 80 mg/160 mg Do. 71&hyph;621 Cholestyramine Resin Bars (Caramel) Parke-Davis, 2800 Plymouth Rd., Ann Arbor, MI 48105. 71&hyph;739 Cholestyramine Resin Bars (Raspberry) Do. 83&hyph;147 Sterile Cortisone Acetate Suspension, USP, 25 mg/mL 50 mg/mL Steris Laboratories,Inc., P.O. Box 23160, Pheonix, AZ 85063&hyph;3160. 84&hyph;356 Edetate Disodium Injection, USP, 150 mg/mL Do. 85&hyph;028 Hydrocortisone Ointment, USP, 1% Clay-Park Labs, Inc., 1700 Bathgate Ave., Bronx, NY 10457. 85&hyph;663 Hydrocortisone Lotion, USP, 1% Do. 86&hyph;466 Aminophylline Oral Solution, USP, 105 mg/5 mL Fisons Corp., 755 Jefferson Rd., P.O. Box 1710, Rochester, NY 14603&hyph;1710. 87&hyph;885 Potassium Chloride for Injection Concentrate, USP Fujisawa USA, Inc. Parkway North Center, Three Parkway North, Deerfield, IL 87&hyph;912 Triamcinolone Acetonide Cream, USP, 0.1% Pharmafair Inc., 110 Kennedy Drive, Hauppauge, NY 11788 87&hyph;921 Triamcinolone Acetonide Cream, USP, 0.025% Do. 87&hyph;922 Triamcinolone Acetonide Cream, USP, 0.5% Do. 88&hyph;032 Sulfacetamide Sodium and Prednisolone Acetate Ophthalmic Ointment, USP, 0.125% Do. 88&hyph;165 Prednisolone Sodium Phosphate Ophthalmic Solution, USP, 1% Do. 88&hyph;385 Sulfacetamide Sodium Ophthalmic Solution, USP, 30% Do. 88&hyph;415 Prednisolone Sodium Phosphate Ophthalmic Solution, USP, 0.125% Do. 89&hyph;914 Hydrocortisone Acetate Cream, USP, 1% Parke-Davis. Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the ANDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective June 22, 1994. Dated: May 10, 1994. Murray M. Lumpkin, Acting Director, Center for Drug Evaluation and Research. [FR Doc. 94&hyph;12554 Filed 5&hyph;20&hyph;94; 8:45 am] BILLING CODE 4160&hyph;01&hyph;F
